Who founded Pathios Therapeutics?

Pathios Therapeutics was founded by Alan Naylor in 2017.

Who are Pathios Therapeutics's investors?

Pathios Therapeutics's investors include Canaan Partners.

Where is Pathios Therapeutics headquartered?

Pathios Therapeutics is headquartered in Oxford, GB.

Pathios Therapeutics

Oxford, GB · Founded 2017 · 20 employees on LinkedIn · 1 known investors

Find your way into Pathios Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Pathios Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers. The company targets cancer immunotherapy applications across a broad range of solid tumors.

Biotech Healthtech Medical Devices

Founders & leadership

Pathios Therapeutics was founded in 2017 by Alan Naylor.

Alan NaylorSenior Drug Discovery Advisor and Co-Founder

Stuart Hughes Chief Scientific OfficerStuart Hughes is Chief Scientific Officer at Pathios Therapeutics, a drug discovery company developing small-molecule immunotherapies for solid tumors. He brings experience in cancer drug discovery and development of novel therapeutic agents.

Investors · 1

Canaan Partnerslisted by Canaan PartnersStamford · $500K – $20M

How we know: Canaan Partners's portfolio page · a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

Undisclosed amountSeries ADec 2019
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 3

PathosPathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Artios PharmaArtios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.

Companies working in the same space as Pathios Therapeutics.

Companies House · registry record

View on Companies House ↗

Registered name: PATHIOS THERAPEUTICS LIMITED
Company number: 10641754
Status: Active
Company type: Private limited company
Incorporated: 27 Feb 2017
Registered office: 99 Park Drive, Milton, Abingdon, OX14 4RY
Nature of business (SIC): 72110 — Research and experimental development on biotechnology
Accounts: last made up to 31 Dec 2025 · next due 30 Sept 2027
Confirmation statement: last made up to 26 Feb 2026 · next due 12 Mar 2027

Current officers · 6

Samantha Ann Harris — secretary, appointed 15 Jun 2022
Brenton Karl Ahrens — director, appointed 28 Aug 2019
Paul Grant Higham — director, appointed 7 Jun 2024
Thomas David Mccarthy — director, appointed 27 Feb 2017
Christopher Dean Nave — director, appointed 9 Sept 2019
Jon Wigginton — director, appointed 14 Jul 2025

Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Pathios Therapeutics | EU-Startupseu-startups.com · Jan 2022

Pathios closes US$8.8M Series A and appoints Stuart Hughes as CEO to accelerate the development of our first-in-class therapies. - Pathios Therapeuticspathiostherapeutics.com · Dec 2019

Frequently asked questions

What does Pathios Therapeutics do?: Pathios Therapeutics is a drug discovery and development company working on small-molecule drugs that block the immune cell receptor GPR65, which senses the acidic tumor microenvironment, with a lead asset (PTT-4256) aimed at treating solid cancers. The company targets cancer immunotherapy applications across a broad range of solid tumors.
Who founded Pathios Therapeutics?: Pathios Therapeutics was founded by Alan Naylor in 2017.
Who are Pathios Therapeutics's investors?: Pathios Therapeutics's investors include Canaan Partners.
Where is Pathios Therapeutics headquartered?: Pathios Therapeutics is headquartered in Oxford, GB.